Screening history of women with cervical cancer: a 6-year study in Aarhus, Denmark by Ingemann-Hansen, O et al.
Short Communication
Screening history of women with cervical cancer: a 6-year study
in Aarhus, Denmark
O Ingemann-Hansen*,1, M Lidang
2, I Niemann
3, J Dinesen
3, U Baandrup
4, H Svanholm
5 and LK Petersen
3
1Institute of Pathology, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark;
2Institute of Pathology, Herlev Hospital, Herlev Ringvej
75, 2730 Herlev, Denmark;
3Department of Gynaecology, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus N, Denmark;
4Institute of
Pathology, Vendsyssel Hospital, Bispensgade 37, 9800 Hjorring, Denmark;
5Institute of Pathology, Regionshospital Randers, Skovlyvej 1, 8900 Randers,
Denmark
To identify possible weaknesses in cervical screening in Aarhus County, 10 years after the programme was introduced, screening
histories were examined. A major problem for the screening programme was that 31% of women were never screened and 61%
under-screened, the latter group being significantly dominated by older women and high-stage tumours.
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The incidence of cervical cancer in Danish women is among the
highest worldwide (14.5 per 100000 women) (Danish National
Board of Health, 2007). In Aarhus County, cytological screening
started in March 1989. Every third year, all women aged 23–59
years receive a personal invitation to have a Papanicolaou (PAP)
smear taken free of charge by their general practitioner. If the
woman does not attend, she receives a re-invitation after 6 months.
The aim of this study was to identify possible weaknesses in the
screening process 10 years after the programme was initiated.
Since every case of cervical cancer arising in a well-organised
screening programme must be considered a possible failure, we
wished to focus on the screening history of women with cervical
cancer diagnosed more than 10 years after screening was
introduced.
MATERIALS AND METHODS
The study population consisted of 286 patients identified
electronically with histologically verified cervical cancer during
the period 1 January 1997 to 30 October 2002 in Aarhus County
(322209 female inhabitants in 2000) by cervical biopsy, cervical
abrades, conisation or hysterectomy specimens. The results of all
previous cervical smears (CS) and histological samples from each
patient were subsequently found in the national pathology
databank, and registered according to the diagnostic categories
of WHO. Information on age and tumour stage at diagnosis
(ad modem FIGO) was obtained from medical records. Patients
were distinguished according to whether they were diagnosed by
the screening programme or because of symptoms such as
abnormal vaginal bleeding, vaginal discharge or pain.
A ‘trigger smear’ was defined for each patient as the
smear leading to further examination. For the majority of patients
with cervical cancer, the trigger smear, or more rarely a
histological sample, started a ‘diagnostic period’ that continued
for up to 5 months. To evaluate the previous screening process
in each woman, we defined an ‘intervention period’ from 5 to 47
months before the diagnosis, during which a possible preinvasive
stage or earlier cancer diagnosis should ideally have been
detected. An intervention period of 42 months was chosen to give
the women a 6-month period to respond to an invitation, as
used previously (Sung et al, 2000). In the collected data, patients
were scored into six different groups based on the screening
history:
(1) ‘Failure to screen in the intervention period’ included women
whose last smear was taken outside the recommended
screening interval;
(2) ‘Never screened’ included women who were never screened
previously;
(3) ‘Failure in detection’ included women having a CS in the
intervention period reported as normal. This group could be
the false-negative results of PAP screening (either due to an
inadequate or poor smear or failure in reading the smear), as
one would expect at least a precancerous diagnosis within 3.5
years before an invasive cancer;
(4) ‘Abnormal CS and adequate follow-up’ included women
having an abnormal smear result in the intervention period
and receiving adequate follow-up afterward;
(5) ‘Failure in follow-up’ included women with abnormal CS in
the intervention period and no or delayed follow-up before the
trigger CS (i.e., a trigger delay). The registered trigger smear
could either be upon a new invitation, after symptoms or the
result of an inadequate follow-up guidance;
(6) ‘Other screening history’ included patients outside the
other groups and consisted of women already in a follow-up
(e.g., after conisation).
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procedures were suggested and abnormal if the cytologist
recommended a follow-up. Non-parametric statistics using SPSS
9.0 and prevalence proportion ratio (PPR) with 95% confidence
interval (95% CI) were determined.
RESULTS
The diagnosis of cervical cancer resulted from referral because of
symptoms in 58% cases, the most frequent being bleeding (48%).
Women over 60 years of age had a PPR of 2.1 (95% CI: 1.8–2.5) for
being diagnosed because of symptoms compared with women less
than 60 years; the latter were more likely to have microscopic/local
disease than older women (PPR 1.6; 95% CI: 1.3–2.0).
As shown in Table 1, the majority (173) of patients had no CS
during the intervention period (groups 1 and 2), and 107 (62%) of
these patients were of an appropriate age for participating in the
screening procedure when diagnosed with cancer. Failure to screen
was associated more commonly with age of over 60 years (PPR 1.7;
95% CI: 1.2–2.3) and with high-stage cancer (PPR 2.0; 95% CI:
1.4–2.9). Inflammation was an associated cytological diagnosis in
the intervention CS among 38% of group 3. Going further back in
screening histories, as many as 75% women had once been
diagnosed with inflammation. Comparing group 3 with the other
groups of ‘well-screened’ patients (groups 4–6) demonstrated a
significant incidence of previous inflammation (PPR 1.6; 95%
CI: 1.1–2.2).
DISCUSSION
The most important finding of this study is the disappointing fact
that despite organised screening since 1989, only 42% of cervical
cancers were diagnosed within the screening programme in
Aarhus County (Denmark).
The facts that 23% of women with cervical cancer never had a
PAP smear and 61% of the cases were non-adherent to screening
(i.e., latest CS more than 3.5 years before the trigger smear)
represent major problems for the programme. Similar problems
have been reported previously, with proportions non-adherent to
the screening programme being 53% (Sung et al, 2000), 54%
(Spence et al, 2007) and 56% (Leyden et al, 2005), and Spence et al
(2007) further estimated that 42% were never screened. Our
findings demonstrate, not surprisingly, that older women are
associated with non-adherence and higher stages of cancer.
However, about two-thirds of non-adherent women were the focus
of the screening programme, so our results definitively confirm
that increasing participation in the screening programme should
be given high priority, to reduce the incidence of cervical cancer
(Lynge et al, 2006).
We were unable to differentiate between rapid-onset cancers and
‘true’ false-negative results. The existence of rapid-onset cancers
is debatable, but we considered that a precancerous smear
diagnosis was to be expected in the previous 3.5-year period
(Wain et al, 1992). Thus, it seems most likely that the women in
group 3 represent 20% false-negative smears due to sampling error
or diagnostic error. A similar false-negative rate has been reported
recently (Spence et al, 2007) and in an earlier Danish study
(Ingeholm and Glenthoj, 1996). We found a significant difference
in favour of PAP smears with inflammation in group 3, an
obscuring factor that may lead to misinterpretation and underlines
the importance of high smear quality (Skehan et al, 1990; Sherman
and Kelly, 1992; Lynge et al, 1993; Lyall and Duncan, 1995).
Our findings indicate that efforts should not only be made to
motivate women to attend the screening, but also in the
organisation of cervical screening. Including women aged 60–69
years in the screening programme will potentially increase the
detection of cervical cancer by 10%. A study on the false-negative
PAP smears has been launched and may identify subgroups of
special interest.
Table 1 Age, clinical stage, histological type of cervical cancer and previous inflammation according to PAP smear histories of 286 women in Aarhus
County (1997–2002)
a
Group division by screening history Bivariate analyses
Group I
(n¼108)
Group II
(n¼65)
Group III
(n¼57)
Group IV
(n¼21)
Group V
(n¼13)
Group VI
(n¼22) I vs II I vs III–VI III vs IV–VI
Variable
Failure to
screen
Never
screened
Failure in
detection
Adequate
follow-up
Inadequate
follow-up Other
Total
(n¼286)
PPR
(95% CI)
PPR
(95% CI)
PPR
(95% CI)
% of all 38 23 20 7 5 7 100
Mean age 49.6 59.2 41.7 36.0 41.3 49.3 49.5
Age
o40 40 (37) 6 (9) 27 (47) 15 (71) 6 (46) 4 (18) 100 (35) 1 1 1
40–59 44 (41) 17 (26) 26 (46) 6 (29) 6 (46) 13 (59) 112 (39) 0.8 (0.7–1.0) 1.1 (0.8–1.5) 1.0 (0.7–1.4)
X60 24 (22) 42 (65) 4 (7) 0 1 (8) 5 (23) 76 (26) 0.4 (0.3–0.6) 1.7 (1.2–2.3) 0.8 (0.4–1.7)
Stage
I.A 31 (29) 6 (9) 26 (46) 11 (52) 5 (38) 8 (36) 87 (30) 1 1 1
I.B–II.A 52 (48) 31 (48) 30 (53) 9 (43) 6 (46) 5 (23) 133 (47) 0.8 (0.6–0.9) 1.3 (1.0–1.9) 1.2 (0.8–1.7)
II.B–IV 21 (19) 25 (38) 1 (1) 1 (5) 2 (16) 2 (9) 52 (18) 0.5 (0.4–0.8) 2.0 (1.4–2.9) 0.3 (0.1–2.0)
Unknown 4 (4) 3 (5) 0 0 0 7 (32) 14 (5) — — —
Histological
Squamous 92 (85) 55 (85) 45 (79) 17 (81) 11 (85) 13 (59) 233 (81) 1.0 (0.7–1.4) 1.4 (0.9–2.1) 1.2 (0.7–1.9)
Non-
squamous
16 (15) 10 (15) 12 (21) 4 (19) 2 (15) 9 (41) 53 (19) 1 1 1
Cytological
Inflammation 57 (53) — 42 (75) 10 (48) 6 (46) 10 (56) 125 (43) — — 1.6 (1.1–2.2)
Abbreviations: CI¼confidence interval; PAP¼Papanicolaou; PPR¼prevalence proportion ratio.
aValues are given in years and as n (%).
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